FILING ANALYSIS · MONDAY, NOVEMBER 16

ENDRA Life Sciences Inc. NDRA — 8-K: Results of Operations and Financial Condition

negative

ENDRA Life Sciences reports a net loss of $1.5 million for the third quarter of 2026 and announces a proposed merger with Noble Africa, which includes a concurrent private placement expected to result in $50 million in gross proceeds, but the company's cash position is limited with only $1.5 million in unrestricted cash, and the transaction is subject to customary closing conditions, including sto

The filing

8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+